Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. NLM AIDSLINE Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.

Nat Med. 1998 Apr;4(4):397-402. Unique Identifier : AIDSLINE MED/98206860
Schneider J; Gilbert SC; Blanchard TJ; Hanke T; Robson KJ; Hannan CM; Becker M; Sinden R; Smith GL; Hill AV; Institute of Molecular Medicine, Nuffield Department of Medicine,; University of Oxford, John Radcliffe Hospital, UK.; joerg.schneider@ndm.ox.ac.uk

Abstract: Immunization with irradiated sporozoites can protect against malaria infection and intensive efforts are aimed at reproducing this effect with subunit vaccines. A particular sequence of subunit immunization with pre-erythrocytic antigens of Plasmodium berghei, consisting of single dose priming with plasmid DNA followed by a single boost with a recombinant modified vaccinia virus Ankara (MVA) expressing the same antigen, induced unprecedented complete protection against P. berghei sporozoite challenge in two strains of mice. Protection was associated with very high levels of splenic peptide-specific interferon-gamma-secreting CD8+ T cells and was abrogated when the order of immunization was reversed. DNA priming followed by MVA boosting may provide a general immunization regime for induction of high levels of CD8+ T cells.
Keywords: *CD8-Positive T-Lymphocytes/IMMUNOLOGY *Immunization, Secondary *Malaria/IMMUNOLOGY *Malaria Vaccines *Plasmodium berghei/IMMUNOLOGY *Vaccines, DNA *Vaccinia Virus/IMMUNOLOGY

KWDcd8-positivet-lymphocytes/immunologyKWDimmunization,secondaryKWDmalaria/immunologyKWDmalariavaccinesKWDplasmodiumberghei/immunologyKWDvaccines,dnaKWDvacciniavirus/immunology
980730
M9871347

Copyright © 1998 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .